A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Novo Nordisk A/S1 site in 1 country62 target enrollmentSeptember 2012

ConditionsInflammation Rheumatoid Arthritis

InterventionsNNC0114-0006 placebo

DrugsNNC0114-0006 placebo

Overview

Phase: Phase 2
Intervention: NNC0114-0006
Conditions: Inflammation
Sponsor: Novo Nordisk A/S
Enrollment: 62
Locations: 1
Primary Endpoint: Change in disease activity score based on 28 joints and c-reactive protein (DAS28-CRP)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy.

Registry

clinicaltrials.gov

Start Date

September 2012

End Date

August 2013

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A diagnosis of RA meeting the 2010 ACR (American College of Rheumatology) classification criteria, obtained at least 6 months prior to dosing with the trial product. (If the diagnosis was made prior to 2010, a diagnosis meeting the 1987 ACR classification criteria is acceptable)
•Active RA characterised by DAS28-CRP (disease activity score based on 28 joints and c-reactive protein) equal to or above 4.5 and at least five tender and five swollen joints (can be the same joints) of the 28 joint count
•Concomitant treatment with MTX above or equal to 15 mg/week for at least 4 months prior to screening, with stable dose of between or equal to 15 mg/week and 25 mg/week for at least 6 weeks prior to screening (MTX doses between 7.5 and 12.5 mg/week are allowed, if patient had intolerance to 15 mg/week)
•Biologic naïve subjects or subjects having been treated with biologics for RA (biologic experienced) provided they meet one of the following criteria: a. Reason for discontinuation of biologic therapy was intolerance (e.g., unable to receive recommended doses or achieve adequate treatment duration because of drug related side effects), b. Discontinued biologic therapy for other reasons than lack of efficacy (primary or secondary failure) or intolerance (e.g., drug holiday)

Exclusion Criteria

•Body mass index (BMI) below or equal to 18.0 or above or equal to 38.0 kg/m\^2
•Subjects with rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome). Subjects with secondary Sjögren's syndrome or stable hypothyroidism are eligible
•Any active or ongoing bacterial infections within 4 weeks prior to randomisation, unless treated and resolved with appropriate therapy (e.g., simple urinary tract infection)
•Any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)
•History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate therapy

Arms & Interventions

Active

Intervention: NNC0114-0006

Placebo

Intervention: placebo

Outcomes

Primary Outcomes

Change in disease activity score based on 28 joints and c-reactive protein (DAS28-CRP)

Time Frame: Week 0, week 12

Secondary Outcomes

Terminal serum half-life (t½)(After second dose administration at week 6)
ACR20/50/70 (20%, 50% or 70% improvement of ACR (American College of Rheumatology) score from baseline)(Week 12)
Change in serum levels of total interleukin-21 (IL-21)(Up to week 12)
Change in Health Assessment Questionnaire - Disability Index score (HAQ-DI)(Week 0, week 12)
Incidence of adverse events (AEs)(Up to week 24)
Incidence of antibodies against NNC0114-0006(Up to Week 24)